CL2016000753A1 - Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells. - Google Patents

Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells.

Info

Publication number
CL2016000753A1
CL2016000753A1 CL2016000753A CL2016000753A CL2016000753A1 CL 2016000753 A1 CL2016000753 A1 CL 2016000753A1 CL 2016000753 A CL2016000753 A CL 2016000753A CL 2016000753 A CL2016000753 A CL 2016000753A CL 2016000753 A1 CL2016000753 A1 CL 2016000753A1
Authority
CL
Chile
Prior art keywords
parkison
dopamine
attenuation
receptor
inhibiting
Prior art date
Application number
CL2016000753A
Other languages
Spanish (es)
Inventor
Rodrigo Pacheco
Hugo Gonzalez
Francisco Contreras
Valentina Ugalde
Daniela Elgueta
Original Assignee
Fund Ciencia Para La Vida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Ciencia Para La Vida filed Critical Fund Ciencia Para La Vida
Priority to CL2016000753A priority Critical patent/CL2016000753A1/en
Priority to PCT/IB2017/051868 priority patent/WO2017168390A2/en
Publication of CL2016000753A1 publication Critical patent/CL2016000753A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/80—Neurotransmitters; Neurohormones
    • C12N2501/815—Dopamine
CL2016000753A 2016-03-31 2016-03-31 Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells. CL2016000753A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CL2016000753A CL2016000753A1 (en) 2016-03-31 2016-03-31 Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells.
PCT/IB2017/051868 WO2017168390A2 (en) 2016-03-31 2017-03-31 Attenuation of neurodegeneration associated with parkinson's disease by inhibition of the dopamine d3 receptor in cd4+ t cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2016000753A CL2016000753A1 (en) 2016-03-31 2016-03-31 Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells.

Publications (1)

Publication Number Publication Date
CL2016000753A1 true CL2016000753A1 (en) 2017-11-10

Family

ID=59963679

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000753A CL2016000753A1 (en) 2016-03-31 2016-03-31 Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells.

Country Status (2)

Country Link
CL (1) CL2016000753A1 (en)
WO (1) WO2017168390A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016474A1 (en) * 2019-07-23 2021-01-28 Fundación Ciencia Para La Vida (Fcv) Ibd therapy by inhibition of drd3 in regulatory t cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2343679A (en) * 1998-11-16 2000-05-17 Alison Miriam Davies Autologous transplantation and method for making cells dormant
AU2002347573A1 (en) * 2001-10-29 2003-05-12 Yeda Research And Development Co. Ltd. Methods and pharmaceutical compositions for dopaminergic modulation of t-cell adhesion and acitivty
AU2003267201B2 (en) * 2002-09-14 2009-04-23 The Gov't Of The U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Structurally rigid dopamine D3 receptor selective ligands and process for making them

Also Published As

Publication number Publication date
WO2017168390A3 (en) 2017-11-16
WO2017168390A2 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
BR112017024618A2 (en) receptor triazole agonists apj.
BR112017005255A2 (en) non-greasy personal care compositions.
MA40770A (en) MERGED IMIDAZOLES PENTACYCLIC DERIVATIVES
DK3331886T3 (en) DOPAMIN-D3 RECEPTOR ANTAGONISTS WITH A BICYCLO PART
UY4430S (en) "MOTORCYCLE".
DK3402785T3 (en) 3- (carboxymethyl) -8-amino-2-oxo-1,3-diaza-spiro [4.5] decane-DERIVATIVES
DK3009689T3 (en) A vehicle's hydraulic system
FR3016379B1 (en) FORMWORK BANK WITH INTEGRATED STAIRCASE.
CL2016000753A1 (en) Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells.
FR3016383B1 (en) FORMWORK BANK WITH ARTICULATED FRAME.
IT201700094491A1 (en) Reactor.
DE112017007065A5 (en) WC BOWL DEVICE WITH MINIMIZED ODORING
ITUA20163369A1 (en) EXTRACTION GUIDE FOR DRAWERS OR SIMILAR EQUIPPED WITH ADJUSTMENT MEANS.
ITUA20163609A1 (en) "MICRO-COGENERATOR".
FR3035461B1 (en) BEARING BEARING EQUIPPED WITH A LOCKING DEVICE
PT2915426T (en) Use of compounds for the containment of symptoms of a known disease for the main agricultural crops.
GB201813247D0 (en) The E.M.S as prepulsion
UA34048S (en) "ARTICULAR RATTAN" POLYMER RIBBON
UA34049S (en) "ARTICULAR RATTAN" POLYMER RIBBON
UA34050S (en) "ARTICULAR RATTAN" POLYMER RIBBON
张明 BRILLIANT YOUTH
GB201405907D0 (en) Capturing the angel's share
UA34207S (en) RING "CHAIL"
GB201620609D0 (en) The bubble straw
FR3034635B1 (en) SEAT WITH REMOVABLE SEAT PLATE.